{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:43:41Z","timestamp":1791902621669,"version":"4.3.4"},"reference-count":309,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2003,7,1]],"date-time":"2003-07-01T00:00:00Z","timestamp":1057017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Rofecoxib (MK-966) is a new generation non-steroidal anti-inflammatory agent (NSAID) that exhibits promising anti-inflammatory, analgesic and antipyretic activity. It selectively inhibits cyclooxygenase (COX)-2 isoenzyme in a dose-dependent manner in man. No significant inhibition of COX-1 is observed with rofecoxib up to doses of 1000 mg. The pharmacokinetics of rofecoxib has been found to be complex and variable. Mean oral bioavailability after single dose of rofecoxib (12.5, 25 or 50 mg) is 93% with tmax varying widely between 2 and 9 h. It is highly plasma-protein bound and is metabolized primarily by cytosolic reductases to inactive metabolites. Rofecoxib is eliminated predominantly by hepatic metabolism with a terminal half-life of approximately 17 h during steady state. Various experimental models and clinical studies have demonstrated rofecoxib to be superior, or at least equivalent, in anti-inflammatory, analgesic and antipyretic efficacy to comparator nonselective NSAIDs in osteoarthritis, rheumatoid arthritis and other pain models. Emerging evidence suggests that rofecoxib may also find potential use as supportive therapy in various pathophysiologic conditions like Alzheimer's disease, and in various malignant tumours and polyps, where COX-2 is overly expressed. Rofecoxib is generally well-tolerated. Analysis of data pooled from several trials suggests that rofecoxib is associated with fewer incidences of clinically symptomatic gastrointestinal ulcers and ulcer complications vis-\u00e0-vis conventional NSAIDs. However, this gastropreserving effect may be negated by concurrent use of low-dose aspirin for cardiovascular risk reduction. Rofecoxib tends to show similar tolerability for renal and cardiothrombotic events as compared with non-naproxen nonselective NSAIDs. No clinically significant drug interaction has been reported for rofecoxib except with diuretics, where it reverses their salt-wasting effect and thus can be clinically exploited in electrolyte-wasting disorders. There is only modest information about the physicochemical and pharmaceutical aspects of rofecoxib. Being poorly water soluble, its drug delivery has been improved using varied formulation approaches. Although it is stable in solid state, rofecoxib is photosensitive and base-sensitive in solution form with its degradation mechanistics elucidated. Analytical determinations of rofecoxib and its metabolites in biological fluids employing HPLC with varied types of detectors have been reported. Isolated studies have also been published on the chromatographic and spectrophotometric assay of rofecoxib and its degradants in bulk samples and pharmaceutical dosage forms. The current article provides an updated overview on the physicochemical, pharmaceutical, pharmacokinetic and pharmacodynamic vistas of rofecoxib.<\/jats:p>","DOI":"10.1211\/0022357021387","type":"journal-article","created":{"date-parts":[[2003,7,17]],"date-time":"2003-07-17T23:06:21Z","timestamp":1058483181000},"page":"859-894","source":"Crossref","is-referenced-by-count":26,"title":["Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects"],"prefix":"10.1093","volume":"55","author":[{"given":"Naveen","family":"Ahuja","sequence":"first","affiliation":[{"name":"University Institute of Pharmaceutical Sciences, Panjab University , Chandigarh 160 014","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amarjit","family":"Singh","sequence":"additional","affiliation":[{"name":"Pharma Research and Development, Panacea Biotec Ltd. , P.O. Lalru, Punjab 140 501,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhupinder","family":"Singh","sequence":"additional","affiliation":[{"name":"University Institute of Pharmaceutical Sciences, Panjab University , Chandigarh 160 014","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2003,7,1]]},"reference":[{"key":"2024103109400857600_cit1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/030097401750065274","article-title":"Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis","volume":"30","author":"Acevedo","year":"2001","journal-title":"Scand. J. Rheumatol."},{"key":"2024103109400857600_cit2","first-page":"204","article-title":"Is rofecoxib safer than naproxen","volume":"50","author":"Adelman","year":"2001","journal-title":"J. Fam. Pract."},{"key":"2024103109400857600_cit3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00006527-200006000-00007","article-title":"Selective COX-2 inhibitors and the surgical patient","volume":"20","author":"Afflitto","year":"2000","journal-title":"Plast. Surg. Nurs."},{"key":"2024103109400857600_cit4","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2165\/00002018-200225070-00007","article-title":"Renal failure associated with the use of celecoxib and rofecoxib","volume":"25","author":"Ahmad","year":"2002","journal-title":"Drug Saf."},{"issue":"Suppl. 4","key":"2024103109400857600_cit5","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0885-3924(02)00374-3","article-title":"Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease","volume":"23","author":"Aisen","year":"2002","journal-title":"J. Pain Symptom Manage."},{"key":"2024103109400857600_cit6","first-page":"523","article-title":"Reverse phase high performance liquid chromatographic determination of rofecoxib in tablets","volume":"38","author":"Ajithadas","year":"2001","journal-title":"Indian Drugs"},{"key":"2024103109400857600_cit7","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/j.1476-5381.1994.tb17169.x","article-title":"Involvement of tyrosine kinase in the induction of cyclooxygenase and nitric oxide synthase by endotoxin in cultured cells","volume":"113","author":"Akaraserennont","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"2024103109400857600_cit8","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/j.1572-0241.2002.05646.x","article-title":"Acute pancreatitis associated with rofecoxib","volume":"97","author":"Amaravadi","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"2024103109400857600_cit9","first-page":"26","article-title":"A rapid and sensitive high-performance liquid chromatography assay for rofecoxib in human serum","volume":"40","author":"Aravind","year":"2002","journal-title":"J. Chromatogr. Sci."},{"key":"2024103109400857600_cit10","volume-title":"Introducing Rofib India's first rofecoxib with the beta cyclodextrin advantage: a scientific brief","author":"Aristo Pharmaceutica Is Limited","year":"2000"},{"key":"2024103109400857600_cit11","first-page":"5","article-title":"COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs","volume":"8","author":"Atkinson","year":"2002","journal-title":"Health News"},{"key":"2024103109400857600_cit12","first-page":"1614","article-title":"Mechanistic studies on the reversible metabolism of rofecoxib to 5-hydroxyrofecoxib in the rat: evidence for transient ring opening of a substituted 2-furanone derivative using stable isotope-labeling techniques","volume":"29","author":"Baillie","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"2024103109400857600_cit13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/00002018-200326010-00005","article-title":"Adverse events associated with rofecoxib therapy: results of a large study in community-derived osteoarthritic patients","volume":"26","author":"Bannwarth","year":"2003","journal-title":"Drug Saf."},{"key":"2024103109400857600_cit14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2253-2-4","article-title":"Single-dose rofecoxib for acute postoperative pain in adults: a quantitative systematic review","volume":"2","author":"Barden","year":"2002","journal-title":"BMC Anesthesiol"},{"key":"2024103109400857600_cit15","first-page":"1053","article-title":"Evaluation of preoperative administration of the cyclooxygenase-2 inhibitor rofecoxib for the treatment of postoperative pain after lumbar disc surgery","volume":"50","author":"Bekker","year":"2002","journal-title":"Neurosurgery"},{"key":"2024103109400857600_cit16","first-page":"49","article-title":"Outcome measurement in osteoarthritis clinical trials","volume":"22","author":"Bellamy","year":"1995","journal-title":"J. Rheumatol."},{"key":"2024103109400857600_cit17","first-page":"1833","article-title":"Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee","volume":"15","author":"Bellamy","year":"1988","journal-title":"J. Rheumatol."},{"key":"2024103109400857600_cit18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1056-8719(97)00016-6","article-title":"Isoenzyme specific cyclooxygenase inhibitors: a whole cell assay system using the human erythroleukemic cell line HEL and the human monocytic cell line mono mac 6","volume":"37","author":"Berg","year":"1997","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"2024103109400857600_cit19","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1034\/j.1398-9995.2001.00206.x","article-title":"Rofecoxib safe in NSAID hypersensitivity","volume":"56","author":"Berges-Gimeno","year":"2001","journal-title":"Allergy"},{"issue":"Suppl. 9","key":"2024103109400857600_cit20","first-page":"195","article-title":"Systemic analgesia after block peripheral","volume":"67","author":"Berti","year":"2001","journal-title":"Minerva Anestesiol"},{"issue":"Suppl. 1","key":"2024103109400857600_cit21","first-page":"SI5","article-title":"Development and clinical application of COX-2-selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis","volume":"69","author":"Bingham","year":"2002","journal-title":"Cleve. Clin. J. Med."},{"key":"2024103109400857600_cit22","first-page":"267","article-title":"Non-steroidal antiinflammatory drugs with selectivity for cyclooxygenase-2 in alzheimer's disease. Rationale and perspectives","volume":"29","author":"Blain","year":"2000","journal-title":"Presse Med."},{"key":"2024103109400857600_cit23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1067\/mai.2002.121531","article-title":"Chronic sinusitis with rofecoxib","volume":"109","author":"Block","year":"2002","journal-title":"J. Allergy Clin. Immunol."},{"key":"2024103109400857600_cit24","volume-title":"Combination of a GABAA alpha 5 inverse agonist and COX-2 inhibitor, NSAID, estrogen or vitamin E","author":"Block","year":"2002"},{"key":"2024103109400857600_cit25","doi-asserted-by":"crossref","first-page":"3D","DOI":"10.1016\/S0002-9149(02)02231-2","article-title":"An evidence-based evaluation of the gastrointestinal safety of coxibs","volume":"89","author":"Bombardier","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"2024103109400857600_cit26","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group","volume":"343","author":"Bombardier","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"2024103109400857600_cit27","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/archinte.162.6.713","article-title":"Aseptic meningitis associated with rofecoxib","volume":"162","author":"Bonnel","year":"2002","journal-title":"Arch. Intern. Med."},{"key":"2024103109400857600_cit28","first-page":"2556","article-title":"Cyclooxygenase-2 overexpression and tumour formation are blocked by sulindac in a murine model of familial adenomatous polyposis","volume":"56","author":"Boolbol","year":"1996","journal-title":"Cancer Res."},{"key":"2024103109400857600_cit29","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/00003086-200112000-00029","article-title":"Cyclooxygenase-2 inhibitor for pain management in osteoid osteoma","volume":"393","author":"Bottner","year":"2001","journal-title":"Clin. Orthop."},{"key":"2024103109400857600_cit30","doi-asserted-by":"crossref","first-page":"65S","DOI":"10.1016\/S0002-9343(99)00369-1","article-title":"Effects of nonsteroidal antiinflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition","volume":"107","author":"Brater","year":"1999","journal-title":"Am. J. Med."},{"issue":"Suppl. 4","key":"2024103109400857600_cit31","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S0885-3924(02)00370-6","article-title":"Renal effects of cyclooxygyenase-2-selective inhibitors","volume":"23","author":"Brater","year":"2002","journal-title":"J. Pain Symptom Manage."},{"key":"2024103109400857600_cit32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000046212","article-title":"Renal effects of COX-2-selective inhibitors","volume":"21","author":"Brater","year":"2001","journal-title":"Am. J. Nephrol."},{"key":"2024103109400857600_cit33","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3949\/ccjm.68.11.957","article-title":"COX-2 inhibitors and cardiovascular risk: point and counterpoint","volume":"68","author":"Brian","year":"2001","journal-title":"Cleve. Clin. J. Med."},{"key":"2024103109400857600_cit34","doi-asserted-by":"crossref","first-page":"433","DOI":"10.5694\/j.1326-5377.2000.tb139277.x","article-title":"COX-2 inhibitors","volume":"173","author":"Brooks","year":"2000","journal-title":"Med. J. Aust."},{"key":"2024103109400857600_cit35","doi-asserted-by":"crossref","first-page":"462","DOI":"10.2165\/00003088-199427060-00005","article-title":"Pharmacokinetic-pharm acodynamic drug interaction with nonsteroidal antiinflammatory drugs","volume":"27","author":"Brouwers","year":"1994","journal-title":"Clin. Pharmacokinet."},{"key":"2024103109400857600_cit36","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1345\/aph.10160","article-title":"Effect of rofecoxib on the antihypertensive activity of lisinopril","volume":"34","author":"Brown","year":"2000","journal-title":"Ann. Pharmacother."},{"key":"2024103109400857600_cit37","first-page":"118","article-title":"MK-0966 50 mg versus ibuprofen 400 mg in post-surgical dental pain","volume":"65","author":"Brown","year":"1999","journal-title":"(abstract) Clin. Pharmacol. Ther."},{"key":"2024103109400857600_cit38","first-page":"118","article-title":"The COX-2 specific inhibitor, MK-0966, is effective in the treatment of primary dysmenorrhoea","volume":"65","author":"Brown","year":"1999","journal-title":"(abstract) Clin. Pharmacol. Ther."},{"issue":"6","key":"2024103109400857600_cit39","first-page":"S51","article-title":"Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a pharmacologist's perspective","volume":"19","author":"Brune","year":"2001","journal-title":"Clin. Exp. Rheumatol."},{"key":"2024103109400857600_cit40","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/ard.50.10.680","article-title":"Drug interactions in arthritic patients","volume":"50","author":"Buchan","year":"1991","journal-title":"Ann. Rheum. Dis."},{"key":"2024103109400857600_cit41","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1161\/01.CIR.0000014927.74465.7F","article-title":"Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice","volume":"105","author":"Burleigh","year":"2002","journal-title":"Circulation"},{"key":"2024103109400857600_cit42","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0","article-title":"Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib phase III protocol 035 study group","volume":"43","author":"Cannon","year":"2000","journal-title":"Arthritis Rheum."},{"key":"2024103109400857600_cit43","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1046\/j.1525-1470.2002.00103.x","article-title":"Rofecoxib-induced instant aquagenic wrinkling of the palms","volume":"19","author":"Carder","year":"2002","journal-title":"Pediatr. Dermatol."},{"key":"2024103109400857600_cit44","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1111\/j.1572-0241.2001.03835.x","article-title":"Severe upper gastrointestinal bleeding during treatment with rofecoxib for osteoarthritis","volume":"96","author":"Caroli","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"2024103109400857600_cit45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0002-9343(86)90905-8","article-title":"Measurement of renal and non-renal eicosanoid synthesis","volume":"81","author":"Catella","year":"1986","journal-title":"Am. J. Med."},{"key":"2024103109400857600_cit46","doi-asserted-by":"crossref","first-page":"28S","DOI":"10.1016\/S0002-9343(00)00683-5","article-title":"Cyclooxygenase inhibition and thrombogenicity","volume":"110","author":"Catella-Lawson","year":"2001","journal-title":"Am. J. Med."},{"key":"2024103109400857600_cit47","first-page":"735","article-title":"Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids","volume":"289","author":"Catella-Lawson","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2024103109400857600_cit48","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Catella-Lawson","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"2024103109400857600_cit49","first-page":"551","article-title":"Rofecoxib [Vioxx, MK-0966; 4-(4\u2032-methylsulfonylphenyl)-3-ph enyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles","volume":"290","author":"Chan","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2024103109400857600_cit50","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/S0149-2918(01)80119-3","article-title":"Rofecoxib versus codeine\/acetaminophen in postoperative dental pain: a double-blind, randomized, placebo- and active comparator-controlled clinical trial","volume":"23","author":"Chang","year":"2001","journal-title":"Clin. Ther."},{"key":"2024103109400857600_cit51","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0149-2918(02)85126-8","article-title":"Comparison of the analgesic efficacy of rofecoxib and enteric-coated diclofenac sodium in the treatment of postoperative dental pain: a randomized, placebo-controlled clinical trial","volume":"24","author":"Chang","year":"2002","journal-title":"Clin. Ther."},{"key":"2024103109400857600_cit52","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0378-4347(99)00565-4","article-title":"Determination of rofecoxib (MK-0966), a cyclooxygenase-2 inhibitor, in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection","volume":"748","author":"Chavez-Eng","year":"2000","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"2024103109400857600_cit53","first-page":"117","article-title":"High-performance liquid chromatographic-tandem mass spectrometric evaluation and determination of stable isotope labeled analogs of rofecoxib in human plasma samples from oral bioavailability studies","volume":"767","author":"Chavez-Eng","year":"2002","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"2024103109400857600_cit54","volume-title":"Clear oil-containing pharmaceutical compositions","author":"Chen","year":"2001"},{"key":"2024103109400857600_cit55","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1172\/JCI5505","article-title":"Angiotensin II stimulates renal cortical cyclooxygenase-2 expression","volume":"103","author":"Cheng","year":"1999","journal-title":"J. Clin. Invest."},{"key":"2024103109400857600_cit56","first-page":"425","article-title":"Selective inhibitors of type 2 cyclooxygenase: less renal effects than the classical non-steroidal antiinflammatory agents","volume":"21","author":"Chiolero","year":"2000","journal-title":"Nephrologie"},{"key":"2024103109400857600_cit57","doi-asserted-by":"crossref","first-page":"214","DOI":"10.5694\/j.1326-5377.2001.tb143099.x","article-title":"COX-2 inhibition and thrombotic tendency: a need for surveillance","volume":"175","author":"Cleland","year":"2001","journal-title":"Med. J. Aust."},{"key":"2024103109400857600_cit58","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00002281-200205000-00005","article-title":"Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use","volume":"14","author":"Crofford","year":"2002","journal-title":"Curr. Opin. Rheumatol."},{"key":"2024103109400857600_cit59","doi-asserted-by":"crossref","first-page":"SI13","DOI":"10.3949\/ccjm.69.Suppl_1.SI13","article-title":"Cyclooxygenase-2-selective inhibitors: translating pharmacology into clinical utility","volume":"69","author":"Cronstein","year":"2002","journal-title":"Cleve. Clin. J. Med."},{"key":"2024103109400857600_cit60","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0009-9236(99)80006-X","article-title":"Dose ranging trial of the effect of MK-0966 in primary dysmenorrhoea. (abstract)","volume":"65","author":"Daniels","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"2024103109400857600_cit61","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/archinte.160.12.1781","article-title":"A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib\/ibuprofen comparator study group","volume":"160","author":"Day","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"2024103109400857600_cit62","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0025-7753(02)72345-2","article-title":"Rofecoxib induced upper gastrontestinal bleeding","volume":"118","author":"de La Serna Higuera","year":"2002","journal-title":"Med. Clin. (Barc)"},{"key":"2024103109400857600_cit63","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s002280050736","article-title":"Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans","volume":"56","author":"Depr\u00e9","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"2024103109400857600_cit64","first-page":"1507","article-title":"Renal tolerance of selective inhibitors of cyclooxygenase type 2","volume":"30","author":"Deray","year":"2001","journal-title":"Presse Med."},{"key":"2024103109400857600_cit65","first-page":"2494","article-title":"Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors","volume":"28","author":"Detora","year":"2001","journal-title":"J. Rheumatol."},{"key":"2024103109400857600_cit66","first-page":"445","article-title":"Prostaglandin endoperoxide synthase: regulation of enzyme expression","volume":"111","author":"DeWitt","year":"1991","journal-title":"Biochim. Biophys. Acta"},{"key":"2024103109400857600_cit67","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00000421-200110000-00005","article-title":"Targeting angiogenic processes by combination rofecoxib and ionizing radiation","volume":"24","author":"Dicker","year":"2001","journal-title":"Am. J. Clin. Oncol."},{"key":"2024103109400857600_cit68","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/378406a0","article-title":"Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase-2","volume":"378","author":"Dinchuk","year":"1995","journal-title":"Nature"},{"key":"2024103109400857600_cit69","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/0016-5085(94)90246-1","article-title":"Up regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomaas","volume":"107","author":"Eberhart","year":"1994","journal-title":"Gastroenterology"},{"key":"2024103109400857600_cit70","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0009-9236(99)70113-X","article-title":"Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model","volume":"65","author":"Ehrich","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"2024103109400857600_cit71","first-page":"2438","article-title":"Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib osteoarthritis pilot study group","volume":"26","author":"Ehrich","year":"1999","journal-title":"J. Rheumatol."},{"key":"2024103109400857600_cit72","first-page":"2635","article-title":"Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis","volume":"27","author":"Ehrich","year":"2000","journal-title":"J. Rheumatol."},{"key":"2024103109400857600_cit73","first-page":"609","article-title":"Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis","volume":"7","author":"Ehrich","year":"2001","journal-title":"Am. J. Manag. Care"},{"key":"2024103109400857600_cit74","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1034\/j.1398-9995.2000.00838.x","article-title":"Rofecoxib should be tried in NSAID hypersensitivity","volume":"55","author":"Enrique","year":"2000","journal-title":"Allergy"},{"key":"2024103109400857600_cit75","volume-title":"Osmotic device within an osmotic device for drug delivery","author":"Faour","year":"2001"},{"key":"2024103109400857600_cit76","volume-title":"NDA approvals for calender year 1999 of December, 1999","author":"FDA","year":"1999"},{"key":"2024103109400857600_cit77","volume-title":"Listing of approved oncology drugs with approved indications","author":"FDA","year":"1999"},{"key":"2024103109400857600_cit78","volume-title":"Drug approvals for April, 2002","author":"FDA","year":"2002"},{"key":"2024103109400857600_cit79","volume-title":"Information on Vioxxr\u0300","author":"FDA","year":"2002"},{"issue":"Suppl. 1","key":"2024103109400857600_cit80","first-page":"SI59","article-title":"Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy","volume":"69","author":"Fendrick","year":"2002","journal-title":"Cleve. Clin. J. Med."},{"key":"2024103109400857600_cit81","first-page":"123","article-title":"Alzheimer's disease, inflammation and non-steroidal antiinflammatory drugs","volume":"102","author":"Ferencik","year":"2001","journal-title":"Bratisl. Lek. Listy."},{"key":"2024103109400857600_cit82","first-page":"F43","article-title":"NS-398 upregulates constitutive cyclooxygenase-2 expression in the M-1 cortical collecting duct cell line","volume":"280","author":"Ferguson","year":"1999","journal-title":"J. Am. Soc. Physiol."},{"key":"2024103109400857600_cit83","doi-asserted-by":"crossref","first-page":"F360","DOI":"10.1152\/ajprenal.1999.277.3.F360","article-title":"Cyclooxygenase-2 expression and function in the medullary thick ascending limb","volume":"277","author":"Ferreri","year":"1999","journal-title":"Am. J. Physiol. (Renal Physiol.)"},{"key":"2024103109400857600_cit84","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJM200108093450607","article-title":"The coxibs, selective inhibitors of cyclooxygenase-2","volume":"345","author":"FitzGerald","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 25","key":"2024103109400857600_cit85","first-page":"S31","article-title":"COX-2 inhibitors and the cardiovascular system","volume":"19","author":"FitzGerald","year":"2001","journal-title":"Clin. Exp. Rheumatol."},{"key":"2024103109400857600_cit86","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1592\/phco.22.5.384.33193","article-title":"Gastrointestinal bleeds associated with rofecoxib","volume":"22","author":"Foral","year":"2002","journal-title":"Pharmacotherapy"},{"key":"2024103109400857600_cit87","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0040-4039(99)01995-4","article-title":"Magnesium mediated carbometallation of propargyl alcohols: direct routes to furans and furanones","volume":"41","author":"Forgione","year":"2000","journal-title":"Tetrahedron Lett."},{"key":"2024103109400857600_cit88","volume-title":"Tyrosine kinase inhibitors","author":"Fraley","year":"2002"},{"key":"2024103109400857600_cit89","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/S0140-6736(02)08393-9","article-title":"Why do COX-2 inhibitors increase risk of cardiovascular events","volume":"359","author":"Frankish","year":"2002","journal-title":"Lancet"},{"key":"2024103109400857600_cit90","first-page":"105","article-title":"Rofecoxib-associated upper gastrointestinal bleed: a case report","volume":"69","author":"Freedman","year":"2002","journal-title":"Mt Sinai. J. Med."},{"key":"2024103109400857600_cit91","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00004836-200204000-00015","article-title":"Rofecoxib: a possible cause of acute colitis","volume":"34","author":"Freitas","year":"2002","journal-title":"J. Clin. Gastroenterol."},{"key":"2024103109400857600_cit92","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0009-9236(99)80007-1","article-title":"MK-966 versus naproxen sodium 550 mg in post-surgical dental pain","volume":"65","author":"Fricke","year":"1999","journal-title":"(abstract) Clin. Pharmacol. Ther."},{"issue":"Suppl. 28","key":"2024103109400857600_cit93","first-page":"6","article-title":"NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal","volume":"18","author":"Fries","year":"1991","journal-title":"J. Rheumatol."},{"key":"2024103109400857600_cit94","doi-asserted-by":"crossref","first-page":"18D","DOI":"10.1016\/S0002-9149(02)02233-6","article-title":"Effects of nonsteroidal antiinflammatory drug therapy on blood pressure and peripheral edema","volume":"89","author":"Frishman","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"2024103109400857600_cit95","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1172\/JCI107987","article-title":"Urinary prostagland ins: identification and origin","volume":"55","author":"Froelich","year":"1975","journal-title":"J. Clin. Invest."},{"key":"2024103109400857600_cit96","volume-title":"Method of treating or inhibiting colonic polyps and colorectal cancer","author":"Frost","year":"2002"},{"key":"2024103109400857600_cit97","first-page":"CD003685","article-title":"Rofecoxib for the treatment of rheumatoid arthritis (Cochrane Review)","volume":"3","author":"Garner","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"key":"2024103109400857600_cit98","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1592\/phco.21.15.1223.33891","article-title":"Clinical implications of drug interactions with coxibs","volume":"21","author":"Garnett","year":"2001","journal-title":"Pharmacotherapy"},{"issue":"Suppl. 1","key":"2024103109400857600_cit99","first-page":"236","article-title":"Comparative blood pressure effects of rofecoxib, celecoxib, and placebo in patients with osteoarthritis: a randomized controlled trial. (abstract)","volume":"60","author":"Geba","year":"2001","journal-title":"Ann. Rheum. Dis."},{"key":"2024103109400857600_cit100","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/jama.287.1.64","article-title":"Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial","volume":"287","author":"Geba","year":"2002","journal-title":"JAMA"},{"key":"2024103109400857600_cit101","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1185\/030079902125000354","article-title":"A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal antiinflammatory agents","volume":"18","author":"Gertz","year":"2002","journal-title":"Curr. Med. Res. Opin."},{"key":"2024103109400857600_cit102","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.2174\/1381612023394917","article-title":"Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol)","volume":"8","author":"Graham","year":"2002","journal-title":"Curr. Pharm. Des."},{"key":"2024103109400857600_cit103","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1177\/009127000004001224","article-title":"A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers","volume":"40","author":"Greenberg","year":"2000","journal-title":"J. Clin. Pharmacol."},{"key":"2024103109400857600_cit104","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/sj.bjp.0703955","article-title":"Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge","volume":"132","author":"Gretzer","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"2024103109400857600_cit105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/(SICI)1098-1128(199603)16:2<181::AID-MED3>3.0.CO;2-X","article-title":"Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date","volume":"16","author":"Griswold","year":"1996","journal-title":"Med. Res. Rev."},{"key":"2024103109400857600_cit106","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1006\/taap.2002.9457","article-title":"Antiangiogenic effect of a highly selective cyclooxygenase-2 inhibitor on gastric ulcer healing in rats","volume":"183","author":"Guo","year":"2002","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"2024103109400857600_cit107","first-page":"1244","article-title":"The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs","volume":"28","author":"Halpin","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"2024103109400857600_cit108","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1124\/dmd.30.6.684","article-title":"The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects","volume":"30","author":"Halpin","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"2024103109400857600_cit109","doi-asserted-by":"crossref","first-page":"10D","DOI":"10.1016\/S0002-9149(02)02232-4","article-title":"Cyclooxygenase-2 inhibition and renal physiology","volume":"89","author":"Harris","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"2024103109400857600_cit110","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1172\/JCI117620","article-title":"Cyclooxygenase-2 is associated with the macula densa of kidney and increases with salt restriction","volume":"94","author":"Harris","year":"1994","journal-title":"J. Clin. Invest."},{"key":"2024103109400857600_cit111","volume-title":"Investigation of the photostability of two COX-2 inhibitors, rofecoxib and etoricoxib, by HPLC using forced degradation","author":"Hartman","year":"2002"},{"key":"2024103109400857600_cit112","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(98)12154-2","article-title":"COX-2 inhibitors","volume":"353","author":"Hawkey","year":"1999","journal-title":"Lancet"},{"key":"2024103109400857600_cit113","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0889-8553(05)70220-X","article-title":"Gastrointestinal safety of COX-2 specific inhibitors","volume":"30","author":"Hawkey","year":"2001","journal-title":"Gastroenterol. Clin. North Am."},{"key":"2024103109400857600_cit114","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D","article-title":"Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The rofecoxib osteoarthritis endoscopy multinational study group","volume":"43","author":"Hawkey","year":"2000","journal-title":"Arthritis Rheum."},{"key":"2024103109400857600_cit115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2036.2001.00894.x","article-title":"Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans","volume":"15","author":"Hawkey","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2024103109400857600_cit116","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1046\/j.1365-2036.2001.01007.x","article-title":"Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials","volume":"15","author":"Hawkey","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2024103109400857600_cit117","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0736-4679(02)00434-1","article-title":"Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet (1)","volume":"22","author":"Hay","year":"2002","journal-title":"J. Emerg. Med."},{"key":"2024103109400857600_cit118","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1517\/14656566.1.5.1053","article-title":"Rofecoxib","volume":"1","author":"Hillson","year":"2000","journal-title":"Expert. Opin. Pharmacother."},{"key":"2024103109400857600_cit119","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1034\/j.1398-9995.2001.056008789.x","article-title":"Rofecoxib as an alternative in aspirin hypersensitivity","volume":"56","author":"Hinrichs","year":"2001","journal-title":"Allergy"},{"key":"2024103109400857600_cit120","volume-title":"Multi-layered pharmaceutical composition for both intraoral and oral administration with polymeric coatings","author":"Hirsh","year":"2002"},{"key":"2024103109400857600_cit121","doi-asserted-by":"crossref","first-page":"81","DOI":"10.18773\/austprescr.2002.073","article-title":"Warfarin, antiplatelet drugs and their interactions","volume":"25","author":"Ho","year":"2002","journal-title":"Aust. Prescriber"},{"issue":"6","key":"2024103109400857600_cit122","first-page":"S15","article-title":"What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective","volume":"19","author":"Hochberg","year":"2001","journal-title":"Clin. Exp. Rheumatol."},{"key":"2024103109400857600_cit123","doi-asserted-by":"crossref","first-page":"F294","DOI":"10.1152\/ajprenal.00347.2001","article-title":"Role of prostanoids in regulation of the renin-angiotensin-aldosterone system by salt intake","volume":"283","author":"Hocherl","year":"2002","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"2024103109400857600_cit124","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/sj.bjp.0704821","article-title":"Cyclo-oxygenase-2 inhibition increases blood pressure in rats","volume":"136","author":"Hocherl","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"2024103109400857600_cit125","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0952-8180(01)00219-7","article-title":"Preoperative oral rofecoxib does not decrease postoperative pain or morphine consumption in patients after radical prostatectomy: a prospective, randomized, doubleblinded, placebo-controlled trial","volume":"13","author":"Huang","year":"2001","journal-title":"J. Clin. Anesth."},{"key":"2024103109400857600_cit126","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0002-9343(00)00470-8","article-title":"A randomized trial measuring faecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects","volume":"109","author":"Hunt","year":"2000","journal-title":"Am. J. Med."},{"key":"2024103109400857600_cit127","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1155\/2002\/516092","article-title":"Recommendations for the appropriate use of antiinflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents","volume":"16","author":"Hunt","year":"2002","journal-title":"Can. J. Gastroenterol."},{"key":"2024103109400857600_cit128","first-page":"265","article-title":"Selective COX-2 inhibitors: towards defining their appropriate clinical role","volume":"9","author":"Husni","year":"2002","journal-title":"J. Clin. Outcome Management"},{"key":"2024103109400857600_cit129","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0168-8278(02)00177-0","article-title":"Rofecoxib-induced cholestatic hepatitis: treatment with molecular adsorbent recycling system (MARS)","volume":"37","author":"Huster","year":"2002","journal-title":"J. Hepatol."},{"key":"2024103109400857600_cit130","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2165\/00003495-200059060-00001","article-title":"COX-2 selective nonsteroidal antiinflammatory drugs: do they really offer any advantages","volume":"59","author":"Jackson","year":"2000","journal-title":"Drugs"},{"key":"2024103109400857600_cit131","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/01.CIR.0000023454.92028.12","article-title":"Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib","volume":"106","author":"Jaeschke","year":"2002","journal-title":"Circulation"},{"key":"2024103109400857600_cit132","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0166-4328(02)00025-6","article-title":"Modulatory role of cyclooxygenase inhibitors in aging- and scopolamine or lipopolysaccharide-induced cognitive dysfunction in mice","volume":"133","author":"Jain","year":"2002","journal-title":"Behav. Brain Res."},{"key":"2024103109400857600_cit133","first-page":"312","article-title":"High performance liquid chromatographic determination of cyclooxygenase II inhibitor rofecoxib in rat and human plasma","volume":"3","author":"Jamali","year":"2000","journal-title":"J. Pharm. Pharm. Sci."},{"key":"2024103109400857600_cit134","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/ki.1997.449","article-title":"Differential regulation of renal cyclooxygenase mRNA by dietary salt intake","volume":"52","author":"Jensen","year":"1997","journal-title":"Kidney Int."},{"key":"2024103109400857600_cit135","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2174\/1389450013348830","article-title":"Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, antiinflammatory drugs with potential utility as anti-cancer agents","volume":"2","author":"Kalgutkar","year":"2001","journal-title":"Curr. Drug Targets"},{"key":"2024103109400857600_cit136","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0009-9236(01)49789-X","article-title":"Low sodium and furosemide-induced stimulation of the renin system in man is mediated by cyclooxygenase 2","volume":"70","author":"Kammerl","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"2024103109400857600_cit137","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1046\/j.1523-1755.2001.00988.x","article-title":"Inhibition of COX-2 counteracts the effects of diuretics in rats","volume":"60","author":"Kammerl","year":"2001","journal-title":"Kidney Int."},{"key":"2024103109400857600_cit138","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1345\/aph.18415","article-title":"The cycloxoxygenase-2 inhibitors: safety and effectiveness","volume":"33","author":"Kaplan-Machlis","year":"1999","journal-title":"Ann. Pharmacother."},{"key":"2024103109400857600_cit139","volume-title":"Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor","author":"Karali","year":"2002"},{"key":"2024103109400857600_cit140","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1053\/gast.1996.v111.pm8690211","article-title":"Characterization of prostagland in G\/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts","volume":"111","author":"Kargman","year":"1996","journal-title":"Gastroenterology"},{"key":"2024103109400857600_cit141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1254\/jjp.89.1","article-title":"Alteration of gastric ulcerogenic and healing responses in rats with adjuvant-induced arthritis","volume":"89","author":"Kato","year":"2002","journal-title":"Jpn. J. Pharmacol."},{"key":"2024103109400857600_cit142","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1211\/0022357011778070","article-title":"Cyclooxygenase-1 and cyclooxygenase-2 selectivity of nonsteroidal antiinflammatory drugs: investigation using human peripheral monocytes","volume":"53","author":"Kato","year":"2001","journal-title":"J. Pharm. Pharmacol."},{"issue":"Suppl. 1","key":"2024103109400857600_cit143","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/S0885-3924(02)00411-6","article-title":"The impact of pain management on quality of life","volume":"24","author":"Katz","year":"2002","journal-title":"J. Pain Symptom Manage."},{"key":"2024103109400857600_cit144","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1073\/pnas.93.6.2317","article-title":"COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex","volume":"93","author":"Kaufman","year":"1996","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2024103109400857600_cit145","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000051790","article-title":"Fixed drug eruption to rofecoxib with cross-reactivity to sulfonamides","volume":"203","author":"Kaur","year":"2001","journal-title":"Dermatology"},{"key":"2024103109400857600_cit146","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1053\/gast.2002.34244","article-title":"Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's oesophagus","volume":"123","author":"Kaur","year":"2002","journal-title":"Gastroenterology"},{"key":"2024103109400857600_cit147","first-page":"2553","article-title":"Urticaria and angioedema from cyclooxygenase-2 inhibitors","volume":"28","author":"Kelkar","year":"2001","journal-title":"J. Rheumatol."},{"key":"2024103109400857600_cit148","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0378-5173(02)00640-3","article-title":"Abinitio structure determination of rofecoxib from powder diffraction data using molecular packing analysis method and direct space method","volume":"252","author":"Kiang","year":"2003","journal-title":"Int. J. Pharm."},{"key":"2024103109400857600_cit149","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/PL00000252","article-title":"The analysis of nonsteroidal antiinflammatory drug selectivity in prostaglandin G\/H synthase (PGHS)-null cells","volume":"50","author":"Kirtikara","year":"2001","journal-title":"Inflamm. Res."},{"key":"2024103109400857600_cit150","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1681\/ASN.V1351261","article-title":"Selective cyclooxygenase-2 inhibition impairs glomerular capillary healing in experimental glomerulonephritis","volume":"13","author":"Kitahara","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"2024103109400857600_cit151","first-page":"F460","article-title":"Localization of cyclooxygenase-1 and \u22122 in adult and foetal human kidney: implication for renal function","volume":"272","author":"K\u00f6mhoff","year":"1997","journal-title":"Am. J. Physiol."},{"key":"2024103109400857600_cit152","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0085-2538(15)46757-2","article-title":"Cyclooxygenase\u22122 selective inhibitors impair glomerulogenesis and renal cortical development","volume":"57","author":"K\u00f6mhoff","year":"2000","journal-title":"Kidney Int."},{"issue":"Suppl. 1","key":"2024103109400857600_cit153","first-page":"SI47","article-title":"Current perspective on the cardiovascular effects of coxibs","volume":"69","author":"Konstam","year":"2002","journal-title":"Cleve. Clin. J. Med."},{"key":"2024103109400857600_cit154","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1161\/hc4401.100078","article-title":"Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib","volume":"104","author":"Konstam","year":"2001","journal-title":"Circulation"},{"key":"2024103109400857600_cit155","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0731-7085(02)00034-1","article-title":"Isolation and characterisation of process-related impurities in rofecoxib","volume":"29","author":"Krishna Reddy","year":"2002","journal-title":"J. Pharm. Biomed. Anal."},{"key":"2024103109400857600_cit156","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1046\/j.1468-2982.2002.00369.x","article-title":"Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study","volume":"22","author":"Krymchantowski","year":"2002","journal-title":"Cephalalgia"},{"key":"2024103109400857600_cit157","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1136\/pmj.78.921.439","article-title":"Fatal haemorrhagic pulmonary oedema and associated angioedema after the ingestion of rofecoxib","volume":"78","author":"Kumar","year":"2002","journal-title":"Postgrad. Med. J."},{"issue":"Suppl. 4","key":"2024103109400857600_cit158","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0885-3924(02)00368-8","article-title":"Gastrointestinal safety of coxibs and outcomes studies: what's the verdict","volume":"23","author":"Laine","year":"2002","journal-title":"J. Pain Symptom Manage"},{"key":"2024103109400857600_cit159","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0016-5085(99)70334-3","article-title":"A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib osteoarthritis endoscopy study group","volume":"117","author":"Laine","year":"1999","journal-title":"Gastroenterology"},{"issue":"Suppl. 1","key":"2024103109400857600_cit160","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/rheumatology\/41.S1.16","article-title":"Clinical experience with cyclooxygenase-2 inhibitors","volume":"41","author":"Lanas","year":"2002","journal-title":"Rheumatology"},{"key":"2024103109400857600_cit161","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.282.20.1929","article-title":"Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs","volume":"282","author":"Langman","year":"1999","journal-title":"JAMA"},{"key":"2024103109400857600_cit162","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1046\/j.1365-2036.1999.00529.x","article-title":"Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen","volume":"13","author":"Lanza","year":"1999","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2024103109400857600_cit163","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1023\/A:1010748316889","article-title":"Gastrointestinal damage induced by celecoxib and rofecoxib in rats","volume":"46","author":"Laudanno","year":"2001","journal-title":"Dig. Dis. Sci."},{"key":"2024103109400857600_cit164","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1091-255X(01)00042-7","article-title":"Reduction of intestinal neoplasia with adenomatous polyposis coli gene replacement and cox-2 inhibition is additive","volume":"6","author":"Lew","year":"2002","journal-title":"J. Gastrointest. Surg."},{"key":"2024103109400857600_cit165","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0092-8674(00)80402-X","article-title":"Multiple female reproductive failures in cyclooxygenase 2 deficient mice","volume":"91","author":"Lim","year":"1997","journal-title":"Cell"},{"key":"2024103109400857600_cit166","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1481803500007508","article-title":"Review of the selective COX-2 inhibitors celecoxib and rofecoxib: focus on clinical aspects","volume":"4","author":"Loewen","year":"2002","journal-title":"Can. J. Emerg. Med."},{"key":"2024103109400857600_cit167","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2125.2002.01572_1.x","article-title":"A possible interaction between lithium and rofecoxib","volume":"53","author":"Lundmark","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2024103109400857600_cit168","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nsb1196-927","article-title":"The structure of human cyclooxygenase-2; conservation and flexibility of the NSAID binding site","volume":"3","author":"Luong","year":"1996","journal-title":"Nat. Struct. Biol."},{"key":"2024103109400857600_cit169","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1572-0241.2002.05608.x","article-title":"Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease","volume":"97","author":"Mahadevan","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"2024103109400857600_cit170","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0149-2918(99)80045-9","article-title":"Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial","volume":"21","author":"Malmstrom","year":"1999","journal-title":"Clin. Ther."},{"key":"2024103109400857600_cit171","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0149-2918(02)80059-5","article-title":"A comparison of rofecoxib versus celecoxib in treating pain after dental surgery: a single-center, randomized, doubleblind, placebo- and active-comparator-controlled, parallel-group, single-dose study using the dental impaction pain model","volume":"24","author":"Malmstrom","year":"2002","journal-title":"Clin. Ther."},{"key":"2024103109400857600_cit172","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S0731-7085(01)00716-6","article-title":"Examination of rofecoxib solution decomposition under alkaline and photolytic stress conditions","volume":"28","author":"Mao","year":"2002","journal-title":"J. Pharm. Biomed. Anal."},{"key":"2024103109400857600_cit173","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2165\/00019053-200119100-00005","article-title":"Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective","volume":"19","author":"Marshall","year":"2001","journal-title":"Pharmacoeconomics"},{"key":"2024103109400857600_cit174","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1378\/chest.121.6.1812","article-title":"Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma","volume":"121","author":"Martin-Garcia","year":"2002","journal-title":"Chest"},{"key":"2024103109400857600_cit175","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2165\/00003495-200161060-00019","article-title":"Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis","volume":"61","author":"Matheson","year":"2001","journal-title":"Drugs"},{"key":"2024103109400857600_cit176","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0021-9673(01)01221-3","article-title":"Improved procedure for the determination of rofecoxib in human plasma involving 96-well solid-phase extraction and fluorescence detection","volume":"949","author":"Matthews","year":"2002","journal-title":"J. Chromatogr. A"},{"key":"2024103109400857600_cit177","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5414\/CNP58073","article-title":"Successful treatment by cyclooxyenase-2 inhibitor of refractory hypokalemia in a patient with Gitelman's syndrome","volume":"58","author":"Mayan","year":"2002","journal-title":"Clin. Nephrol."},{"key":"2024103109400857600_cit178","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0165-0173(95)00011-9","article-title":"The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases","volume":"21","author":"McGeer","year":"1995","journal-title":"Brain Res. Rev."},{"key":"2024103109400857600_cit179","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00000441-200204000-00003","article-title":"Cox-2 inhibitors: today and tomorrow","volume":"323","author":"McMurray","year":"2002","journal-title":"Am. J. Med. Sci."},{"key":"2024103109400857600_cit180","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1016\/S0021-9258(18)53294-4","article-title":"Differential inhibition of prostagland in endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal antiinflammatory drugs","volume":"268","author":"Meade","year":"1993","journal-title":"J. Biol. Chem."},{"key":"2024103109400857600_cit181","first-page":"139","article-title":"Ex vivo assay of COX-2 inhibition predicts analgesic efficacy in post-surgical dental pain with MK-966. (abstract)","volume":"63","author":"Mehlisch","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"key":"2024103109400857600_cit182","volume-title":"VIOXX (rofecoxib tablets and oral suspension)","author":"Merck & Co., Inc.","year":"1998"},{"key":"2024103109400857600_cit183","first-page":"389","article-title":"Rofecoxib reduces perioperative morphine consumption for abdominal hysterectomy and laparoscopic gastric banding","volume":"30","author":"Meyer","year":"2002","journal-title":"Anaesth. Intensive Care"},{"key":"2024103109400857600_cit184","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/sj.bjp.0701112","article-title":"Selective induction of cyclooxygenase-2 activity in the permanent human endothelial cell line HUV-EC-C: biochemical and pharmacological characterization","volume":"121","author":"Miralpeix","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"2024103109400857600_cit185","doi-asserted-by":"crossref","first-page":"11693","DOI":"10.1073\/pnas.90.24.11693","article-title":"Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase","volume":"90","author":"Mitchell","year":"1994","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2024103109400857600_cit186","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1053\/gast.1997.v112.pm9024292","article-title":"Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by specific antagonist delays healing in mice","volume":"112","author":"Mizuno","year":"1997","journal-title":"Gastroenterology"},{"key":"2024103109400857600_cit187","doi-asserted-by":"crossref","first-page":"451","DOI":"10.14219\/jada.archive.2001.0207","article-title":"Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice","volume":"132","author":"Moore","year":"2001","journal-title":"J. Am. Dent. Assoc."},{"key":"2024103109400857600_cit188","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0149-2918(99)80016-2","article-title":"Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial","volume":"21","author":"Morrison","year":"1999","journal-title":"Clin. Ther."},{"key":"2024103109400857600_cit189","first-page":"504","article-title":"Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhoea: a randomized controlled trial","volume":"94","author":"Morrison","year":"1999","journal-title":"Obstet. Gynecol."},{"key":"2024103109400857600_cit190","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.14219\/jada.archive.2000.0119","article-title":"The optimal analgesic dose of rofecoxib: Overview of six randomized controlled trials","volume":"131","author":"Morrison","year":"2000","journal-title":"J. Am. Dent. Assoc."},{"key":"2024103109400857600_cit191","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0006-2952(02)00842-0","article-title":"Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events","volume":"63","author":"Mukherjee","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"2024103109400857600_cit192","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jama.286.8.954","article-title":"Risk of cardiovascular events associated with selective COX-2 inhibitors","volume":"286","author":"Mukherjee","year":"2001","journal-title":"JAMA"},{"key":"2024103109400857600_cit193","volume-title":"Process for the preparation of a fast dissolving dosage form","author":"Murpani","year":"2002"},{"key":"2024103109400857600_cit194","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1097\/00042737-200112000-00001","article-title":"Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal antiinflammatory drugs","volume":"13","author":"Naesdal","year":"2001","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"2024103109400857600_cit195","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1081-1206(10)62017-0","article-title":"Tolerability of rofecoxib in patients with cutaneous adverse reactions to nonsteroidal antiinflammatory drugs","volume":"88","author":"Nettis","year":"2002","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"2024103109400857600_cit196","first-page":"201","article-title":"Renal tolerability of three commonly employed non-steroidal antiinflammatory drugs in elderly patients with osteoarthritis","volume":"20","author":"Niccoli","year":"2002","journal-title":"Clin. Exp. Rheumatol."},{"key":"2024103109400857600_cit197","first-page":"3669","article-title":"Cyclooxygenase-2 enzyme inhibitors: place in therapy","volume":"61","author":"Noble","year":"2000","journal-title":"Am. Fam. Physician."},{"key":"2024103109400857600_cit198","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00002018-200225030-00003","article-title":"Cyclo-oxygenase-2 inhibitors and the kidney: a case for caution","volume":"25","author":"Noroian","year":"2002","journal-title":"Drug Saf."},{"key":"2024103109400857600_cit199","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1111\/j.1572-0241.2001.03905.x","article-title":"Rofecoxib-induced renal dysfunction in a patient with compensated cirrhosis and heart failure","volume":"96","author":"Ofran","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"2024103109400857600_cit200","article-title":"Coxibs in clinical practice: towards a Saskatchewan consensus","volume-title":"RxFiles; the RxFiles academic program","author":"Olszynski","year":"2002"},{"key":"2024103109400857600_cit201","first-page":"1733","article-title":"Chemoprevention of intestinal polyposis in the Apcdelta 716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor","volume":"61","author":"Oshima","year":"2001","journal-title":"Cancer Res."},{"key":"2024103109400857600_cit202","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0149-2918(02)80011-X","article-title":"Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension","volume":"24","author":"Osterhaus","year":"2002","journal-title":"Clin. Ther."},{"key":"2024103109400857600_cit203","doi-asserted-by":"crossref","first-page":"14583","DOI":"10.1073\/pnas.251543298","article-title":"A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin","volume":"98","author":"Ouellet","year":"2001","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2024103109400857600_cit204","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1046\/j.1365-2222.2002.01260.x","article-title":"Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and\/or non-steroidal antiinflammatory drugs","volume":"32","author":"Pacor","year":"2002","journal-title":"Clin. Exp. Allergy"},{"key":"2024103109400857600_cit205","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/humrep\/16.7.1323","article-title":"Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study","volume":"16","author":"Pall","year":"2001","journal-title":"Hum. Reprod."},{"key":"2024103109400857600_cit206","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1053\/gast.2001.29469","article-title":"Discussion on rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostagland in production","volume":"121","author":"Palmer","year":"2001","journal-title":"Gastroenterology"},{"issue":"Suppl. 11","key":"2024103109400857600_cit207","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.7556\/jaoa.1999.99.11.S18","article-title":"COX-2-specific inhibition: implications for clinical practice","volume":"99","author":"Pascucci","year":"1999","journal-title":"J. Am. Osteopath. Assoc."},{"key":"2024103109400857600_cit208","volume-title":"Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents","author":"Patel","year":"2001"},{"key":"2024103109400857600_cit209","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0304-3835(02)00003-4","article-title":"Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: effect of celecoxib and rofecoxib","volume":"180","author":"Patti","year":"2002","journal-title":"Cancer Lett."},{"key":"2024103109400857600_cit210","first-page":"415","article-title":"First spontaneous reports of adverse reactions to the new selective COX-2 non-steroidal antiinflammatory drugs","volume":"118","author":"Pedros","year":"2002","journal-title":"Med. Clin. (Barc.)"},{"key":"2024103109400857600_cit211","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0002-9343(01)00757-4","article-title":"Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal antiinflammatory drugs","volume":"111","author":"Perazella","year":"2001","journal-title":"Am. J. Med."},{"key":"2024103109400857600_cit212","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1046\/j.1526-4610.2002.02131.x","article-title":"Hemicrania continua responds to cyclooxygenase-2 inhibitors","volume":"42","author":"Peres","year":"2002","journal-title":"Headache"},{"key":"2024103109400857600_cit213","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1046\/j.1468-2982.2000.00029.x","article-title":"Hemicrania continua responsive to rofecoxib","volume":"20","author":"Peres","year":"2000","journal-title":"Cephalalgia"},{"key":"2024103109400857600_cit214","first-page":"A377","article-title":"COX-2 inhibitor non-steroidal antiinflammatory drugs, myth or reality","volume":"22","author":"Peretz","year":"2001","journal-title":"Rev. Med. Brux."},{"issue":"Suppl. 1","key":"2024103109400857600_cit215","first-page":"SI31","article-title":"Gastrointestinal safety and tolerability of nonselective nonsteroidal antiinflammatory agents and cyclooxygenase-2-selective inhibitors","volume":"69","author":"Peura","year":"2002","journal-title":"Cleve. Clin. J. Med."},{"key":"2024103109400857600_cit216","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/bja\/88.1.72","article-title":"Double-blind, placebo-controlled analgesic study of ibuprofen or rofecoxib in combination with paracetamol for tonsillectomy in children","volume":"88","author":"Pickering","year":"2002","journal-title":"Br. J. Anaesth."},{"key":"2024103109400857600_cit217","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/367243a0","article-title":"The X-ray crystal structure of the membrane protein prostagland in H2 synthase-1","volume":"367","author":"Picot","year":"1994","journal-title":"Nature"},{"key":"2024103109400857600_cit218","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1081-1206(10)61912-6","article-title":"Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions","volume":"89","author":"Quiralte","year":"2002","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"2024103109400857600_cit219","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0731-7085(01)00493-9","article-title":"LC determination of rofecoxib in bulk and pharmaceutical formulations","volume":"26","author":"Radhakrishna","year":"2001","journal-title":"J. Pharm. Biomed. Anal."},{"key":"2024103109400857600_cit220","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0026-265X(01)00153-9","article-title":"Adsorptive stripping square-wave voltammetric behavior of rofecoxib","volume":"72","author":"Radi","year":"2002","journal-title":"Microchemical J."},{"key":"2024103109400857600_cit221","first-page":"77","article-title":"Rofecoxib: a new selective COX-2 inhibitor","volume":"47","author":"Rajadhyaksha","year":"2001","journal-title":"J. Postgrad. Med."},{"key":"2024103109400857600_cit222","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1615\/JEnvironPatholToxicolOncol.v21.i2.90","article-title":"Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors","volume":"21","author":"Reddy","year":"2002","journal-title":"J. Environ. Pathol. Toxicol. Oncol."},{"key":"2024103109400857600_cit223","first-page":"39","article-title":"UV and visible spectrophotometeric methods for the determination of rofecoxib","volume":"39","author":"Reddy","year":"2002","journal-title":"Indian Drugs"},{"key":"2024103109400857600_cit224","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3810\/pgm.1999.10.1.704","article-title":"When to try COX-2-specific inhibitors. Safer than standard NSAIDs in some situations","volume":"106","author":"Rehman","year":"1999","journal-title":"Postgrad. Med."},{"key":"2024103109400857600_cit225","first-page":"40","article-title":"Efficacy of single-dose and multidose rofecoxib in the treatment of postorthopedic surgery pain","volume":"30","author":"Reicin","year":"2001","journal-title":"Am. J. Orthop."},{"key":"2024103109400857600_cit226","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0002-9149(01)02201-9","article-title":"Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal antiinflammatory drugs (ibuprofen, diclofenac, and nabumetone)","volume":"89","author":"Reicin","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"2024103109400857600_cit227","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1046\/j.1523-1755.2002.00435.x","article-title":"Role of cyclooxygenase-2 in hyperprostaglandin E syndrome\/antenatal Bartter syndrome","volume":"62","author":"Reinalter","year":"2002","journal-title":"Kidney Int."},{"key":"2024103109400857600_cit228","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/sj.jhh.1001411","article-title":"The different patterns of blood pressure elevation by rofecoxib and nabumetone","volume":"16","author":"Reitblat","year":"2002","journal-title":"J. Hum. Hypertens."},{"key":"2024103109400857600_cit229","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1107\/S0108270100001062","article-title":"Vioxx, a COX-II inhibitor","volume":"56","author":"Rekha","year":"2000","journal-title":"Acta Crystallogr. Sect. C Cryst. Struct. Commun."},{"key":"2024103109400857600_cit230","first-page":"1221","article-title":"Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery","volume":"91","author":"Reuben","year":"2000","journal-title":"Anesth. Analg."},{"key":"2024103109400857600_cit231","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1213\/00000539-200201000-00010","article-title":"The preemptive analgesic effect of rofecoxib after ambulatory arthroscopic knee surgery","volume":"94","author":"Reuben","year":"2002","journal-title":"Anesth. Analg."},{"key":"2024103109400857600_cit232","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1054\/arth.2002.27677","article-title":"Evaluation of the safety and efficacy of the perioperative administration of rofecoxib for total knee arthroplasty","volume":"17","author":"Reuben","year":"2002","journal-title":"J. Arthroplasty"},{"key":"2024103109400857600_cit233","first-page":"1276","article-title":"Expression of cyclooxygenase-2 in human gastric carcinoma","volume":"57","author":"Ristimaki","year":"1997","journal-title":"Cancer Res."},{"key":"2024103109400857600_cit234","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.2337\/diabetes.47.9.1379","article-title":"Dominance of cyclooxygenase-2 in the regulation of pancreatic islet prostagland in synthesis","volume":"47","author":"Robertson","year":"1998","journal-title":"Diabetes"},{"key":"2024103109400857600_cit235","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/S0140-6736(00)05083-2","article-title":"Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib","volume":"357","author":"Rocha","year":"2001","journal-title":"Lancet"},{"key":"2024103109400857600_cit236","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1124\/dmd.31.2.224","article-title":"Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers","volume":"31","author":"Rodrigues","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"2024103109400857600_cit237","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/archinte.1986.00360180057008","article-title":"Nonsteroidal antiinflammatory drug gastropathy: we started it \u2013 can we stop it?","volume":"146","author":"Roth","year":"1986","journal-title":"Arch. Intern. Med."},{"key":"2024103109400857600_cit238","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/archfami.9.10.1124","article-title":"Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal antiinflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis studies group","volume":"9","author":"Saag","year":"2000","journal-title":"Arch. Fam. Med."},{"key":"2024103109400857600_cit239","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1081-1206(10)62226-0","article-title":"Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions","volume":"87","author":"Sanchez Borges","year":"2001","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"2024103109400857600_cit240","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/PL00000287","article-title":"Effect of rofecoxib on nociception and the serotonin system in the rat brain","volume":"51","author":"Sandrini","year":"2002","journal-title":"Inflamm. Res."},{"key":"2024103109400857600_cit241","first-page":"751","article-title":"Pharma-clinics. The drug of the month. Rofecoxib (Vioxx)","volume":"55","author":"Scheen","year":"2000","journal-title":"Rev. Med. Liege."},{"issue":"Suppl. 1","key":"2024103109400857600_cit242","first-page":"SI40","article-title":"Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors","volume":"69","author":"Scheiman","year":"2002","journal-title":"Cleve. Clin. J. Med."},{"key":"2024103109400857600_cit243","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0149-2918(01)80041-2","article-title":"Osteoarthritis management: the role of cyclooxygenase-2-selective inhibitors","volume":"23","author":"Schnitzer","year":"2001","journal-title":"Clin. Ther."},{"issue":"Suppl. 1","key":"2024103109400857600_cit244","first-page":"SI20","article-title":"COX-2-selective inhibitors in the treatment of arthritis","volume":"69","author":"Schnitzer","year":"2002","journal-title":"Cleve. Clin. J. Med."},{"key":"2024103109400857600_cit245","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S0149-2918(99)80048-4","article-title":"The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II rofecoxib rheumatoid arthritis study group","volume":"21","author":"Schnitzer","year":"1999","journal-title":"Clin. Ther."},{"key":"2024103109400857600_cit246","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0149-2918(02)85048-2","article-title":"A comparison of the renal and cardiovascular safety of celecoxib and rofecoxib","volume":"24","author":"Schoors","year":"2002","journal-title":"Clin. Ther."},{"issue":"Suppl.","key":"2024103109400857600_cit247","first-page":"A113","article-title":"Influence of selective cyclooxygenase-2 inhibitor, MK-0966, on ethinylestradiol (EE) and norethindrone (NET) serum concentrations. (abstract)","volume":"52","author":"Schwartz","year":"1997","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"2024103109400857600_cit248","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0009-9236(99)90087-5","article-title":"Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans","volume":"65","author":"Schwartz","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"2024103109400857600_cit249","first-page":"137","article-title":"Pharmacokinetics of rofecoxib in mild to moderate hepatic insufficiency (HI). (abstract)","volume":"67","author":"Schwartz","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"2024103109400857600_cit250","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1067\/mcp.2000.112244","article-title":"The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin","volume":"68","author":"Schwartz","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"2024103109400857600_cit251","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1177\/00912700122012616","article-title":"Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients","volume":"41","author":"Schwartz","year":"2001","journal-title":"J. Clin. Pharmacol."},{"key":"2024103109400857600_cit252","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/00912700122009755","article-title":"Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers","volume":"41","author":"Schwartz","year":"2001","journal-title":"J. Clin. Pharmacol."},{"key":"2024103109400857600_cit253","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/00912700222011139","article-title":"Effect of rofecoxib on the pharmacokinetics of chronically administered oral contraceptives in healthy female volunteers","volume":"42","author":"Schwartz","year":"2002","journal-title":"J. Clin. Pharmacol."},{"key":"2024103109400857600_cit254","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/0091270002239828","article-title":"Effect of rofecoxib on prednisolone and prednisone pharmacokinetics in healthy subjects","volume":"43","author":"Schwartz","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"2024103109400857600_cit255","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2165\/00003495-199958030-00016","article-title":"Rofecoxib","volume":"58","author":"Scott","year":"1999","journal-title":"Drugs"},{"key":"2024103109400857600_cit256","volume-title":"US FDA draft label for Celebrex (Celecoxib capsules)","author":"Searle & Co., Inc.","year":"1999"},{"key":"2024103109400857600_cit257","volume-title":"Information on clinical pharmacology of Valdecoxib","author":"Searle Ltd","year":"2002"},{"key":"2024103109400857600_cit258","first-page":"49","article-title":"NSAIDs and COX-2 inhibitors: selective vs standard use","volume":"3","author":"Seibold","year":"2001","journal-title":"Med. Crossfire"},{"key":"2024103109400857600_cit259","volume-title":"Dermal therapeutic system containing non-steroidal antiphlogistics with selective COX-2 inhibition","author":"Selzer","year":"2002"},{"key":"2024103109400857600_cit260","first-page":"762","article-title":"Inhibitory effect of 3,4-diaryl-3-pyrrolin-2-one derivatives on cyclooxygenase 1 and 2 in murine peritoneal macrophages","volume":"23","author":"Shen","year":"2002","journal-title":"Acta. Pharmacol. Sin."},{"key":"2024103109400857600_cit261","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/gut.47.4.527","article-title":"COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin","volume":"47","author":"Sigthorsson","year":"2000","journal-title":"Gut"},{"key":"2024103109400857600_cit262","volume-title":"Method of treating migraines and pharmaceutical compositions","author":"Simitchieva","year":"2002"},{"key":"2024103109400857600_cit263","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0889-8553(05)70226-0","article-title":"COX-2 inhibitors. Are they nonsteroidal antiinflammatory drugs with a better safety profile?","volume":"30","author":"Simon","year":"2001","journal-title":"Gastroenterol. Clin. North Am."},{"issue":"Suppl. 1","key":"2024103109400857600_cit264","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0885-3924(02)00410-4","article-title":"Role of cox-2 inhibitors in the evolution of acute pain management","volume":"24","author":"Sinatra","year":"2002","journal-title":"J. Pain Symptom Manage."},{"key":"2024103109400857600_cit265","volume-title":"Antiinflammatory and analgesic composition containing COX-2 inhibitors for topical and transdermal uses","author":"Singh","year":"2001"},{"key":"2024103109400857600_cit266","article-title":"Studies on dissolution enhancement of rofecoxib using water-soluble carriers","volume-title":"National seminar on pharmaceutics in the light of drug delivery challenges","author":"Singh","year":"2003"},{"key":"2024103109400857600_cit267","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1001\/archinte.1996.00440130066007","article-title":"Gastrointestinal tract complications of non-steroidal antiinflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study","volume":"156","author":"Singh","year":"1996","journal-title":"Arch. Intern. Med."},{"key":"2024103109400857600_cit268","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1211\/0022357001774255","article-title":"Nimesulide: some pharmaceutical and pharmacological aspects \u2013 an update","volume":"52","author":"Singla","year":"2000","journal-title":"J. Pharm. Pharmacol."},{"key":"2024103109400857600_cit269","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/106002809502900612","article-title":"Recent advances: the cytochrome P450 enzymes","volume":"29","author":"Slaughter","year":"1995","journal-title":"Ann. Pharmacother."},{"key":"2024103109400857600_cit270","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0065-2776(08)60430-7","article-title":"Prostaglandin endoperoxide H synthases-1 and \u22122","volume":"62","author":"Smith","year":"1996","journal-title":"Adv. Immunol."},{"key":"2024103109400857600_cit271","doi-asserted-by":"crossref","first-page":"33157","DOI":"10.1074\/jbc.271.52.33157","article-title":"Prostaglandin endoperoxide H synthases (cyclooxygenase)-1 and \u22122","volume":"271","author":"Smith","year":"1996","journal-title":"J. Biol. Chem."},{"key":"2024103109400857600_cit272","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1185\/0300799039117031","article-title":"Patient and physician satisfaction with rofecoxib in osteoarthritis: results of the EVA (experience with VIOXX in arthritis) survey","volume":"17","author":"Steinfeld","year":"2001","journal-title":"Curr. Med. Res. Opin."},{"issue":"Suppl. 1","key":"2024103109400857600_cit273","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/rheumatology\/41.S1.23","article-title":"Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxib","volume":"41","author":"Steinfeld","year":"2002","journal-title":"Rheumatology"},{"key":"2024103109400857600_cit274","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1067\/mai.2001.116290","article-title":"Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma","volume":"108","author":"Stevenson","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"2024103109400857600_cit275","volume-title":"Porous drug matrices and methods of manufacture thereof","author":"Straub","year":"2002"},{"key":"2024103109400857600_cit276","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11926-001-0055-9","article-title":"COX-2 inhibitors in rheumatoid arthritis","volume":"3","author":"Sundy","year":"2001","journal-title":"Curr. Rheumatol. Rep."},{"key":"2024103109400857600_cit277","volume-title":"Microemulsion preconcentrates as pharmaceutical formulations for anti-inflammatory compounds with low solubility","author":"Supersaxo","year":"2002"},{"key":"2024103109400857600_cit278","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-133-1-200007040-00002","article-title":"Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial","volume":"133","author":"Swan","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"2024103109400857600_cit279","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1046\/j.1365-2222.2001.01075.x","article-title":"Safety of a specific COX-2 inhibitor in aspirin-induced asthma","volume":"31","author":"Szczeklik","year":"2001","journal-title":"Clin. Exp. Allergy"},{"key":"2024103109400857600_cit280","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0928-4257(01)00005-5","article-title":"Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs","volume":"95","author":"Tanaka","year":"2001","journal-title":"J. Physiol. Paris"},{"issue":"Suppl. 2","key":"2024103109400857600_cit281","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1046\/j.1365-2036.16.s2.22.x","article-title":"Up-regulation of COX-2 by inhibition of COX-1 in the rat: a key to NSAID-induced gastric injury","volume":"16","author":"Tanaka","year":"2002","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2024103109400857600_cit282","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1124\/jpet.300.3.754","article-title":"Up-regulation of cyclooxygen ase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal antiinflammatory drug-induced intestinal damage","volume":"300","author":"Tanaka","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2024103109400857600_cit283","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1055\/s-2001-17519","article-title":"Synthesis of rofecoxib, (MK 0966, Vioxx 4-(4\u2032-methylsulphonylphenyl)-3-phenyl-2(5 H)-furanone), a selective and orally active inhibitor of cyclooxygenase-2","volume":"12","author":"Th\u00e9rien","year":"2001","journal-title":"Synthesis"},{"key":"2024103109400857600_cit284","first-page":"112","article-title":"A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis","volume":"13","author":"Truitt","year":"2001","journal-title":"Aging (Milano)"},{"key":"2024103109400857600_cit285","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1432-1033.1996.t01-1-00557.x","article-title":"Secretory non-pancreatic phospholipase A2 and cyclooxygenase-2 expression by tracheobronchial smooth muscle cells","volume":"235","author":"Vadas","year":"1996","journal-title":"Eur. J. Biochem."},{"key":"2024103109400857600_cit286","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1177\/009127000004001005","article-title":"Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers","volume":"40","author":"Van Hecken","year":"2000","journal-title":"J. Clin. Pharmacol."},{"key":"2024103109400857600_cit287","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/newbio231232a0","article-title":"Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs","volume":"231","author":"Vane","year":"1971","journal-title":"Nat. New Biol."},{"key":"2024103109400857600_cit288","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01630479","article-title":"New insights into the mode of action of antiinflammatory drugs","volume":"44","author":"Vane","year":"1995","journal-title":"Inflamm. Res."},{"key":"2024103109400857600_cit289","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1161\/hc4901.101350","article-title":"Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation","volume":"104","author":"Verma","year":"2001","journal-title":"Circulation"},{"key":"2024103109400857600_cit290","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000046077","article-title":"Acute, anuric renal failure associated with two doses of a cyclooxygenase-2 inhibitor","volume":"89","author":"Wahba","year":"2001","journal-title":"Nephron"},{"key":"2024103109400857600_cit291","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1001\/archinte.160.19.2998","article-title":"Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis","volume":"160","author":"Watson","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"2024103109400857600_cit292","first-page":"6","article-title":"Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs","volume":"3","author":"Watson","year":"2001","journal-title":"Med. Gen. Med."},{"key":"2024103109400857600_cit293","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0149-2918(01)80112-0","article-title":"Rofecoxib: clinical pharmacology and clinical experience","volume":"23","author":"Weaver","year":"2001","journal-title":"Clin. Ther."},{"key":"2024103109400857600_cit294","first-page":"3449","article-title":"GI events leading to death in association with celecoxib and rofecoxib","volume":"96","author":"Weaver","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"2024103109400857600_cit295","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0378-4347(01)00256-0","article-title":"Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans","volume":"760","author":"Werner","year":"2001","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"2024103109400857600_cit296","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.7326\/0003-4819-134-11-200106050-00018","article-title":"Cyclooxygenase-2 inhibition and renal function","volume":"134","author":"Whelton","year":"2001","journal-title":"Ann. Intern. Med."},{"key":"2024103109400857600_cit297","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00045391-200103000-00003","article-title":"Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients","volume":"8","author":"Whelton","year":"2001","journal-title":"Am. J. Ther."},{"key":"2024103109400857600_cit298","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1053\/gast.2001.22432","article-title":"Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostagland in production","volume":"120","author":"Wight","year":"2001","journal-title":"Gastroenterology"},{"key":"2024103109400857600_cit299","first-page":"2929","article-title":"Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's oesophagus and associated adenocarcinom as","volume":"58","author":"Wilson","year":"1998","journal-title":"Cancer Res."},{"key":"2024103109400857600_cit300","volume-title":"Wockhardt second quarter 2002 financial results","author":"","year":"2002"},{"key":"2024103109400857600_cit301","doi-asserted-by":"crossref","first-page":"394","DOI":"10.7326\/0003-4819-133-5-200009050-00024","article-title":"Acute renal failure associated with rofecoxib","volume":"133","author":"Wolf","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"2024103109400857600_cit302","first-page":"467","article-title":"Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy","volume":"29","author":"Wolfe","year":"2002","journal-title":"J. Rheumatol."},{"key":"2024103109400857600_cit303","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s000110050063","article-title":"Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells","volume":"46","author":"Wong","year":"1997","journal-title":"Inflamm. Res"},{"key":"2024103109400857600_cit304","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0378-4347(99)00215-7","article-title":"Determination of rofecoxib, a cyclooxygenase-2 specific inhibitor, in human plasma using high-performance liquid chromatography with post-column photochemical derivatization and fluorescence detection","volume":"730","author":"Woolf","year":"1999","journal-title":"J. Chromatogr. B. Biomed. Sci. Appl."},{"key":"2024103109400857600_cit305","first-page":"2133","article-title":"Nephrotoxicity of selective COX-2 inhibitors","volume":"28","author":"Woywodt","year":"2001","journal-title":"J. Rheumatol."},{"key":"2024103109400857600_cit306","first-page":"37","article-title":"Synthesis of new cyclooxygenase-2 inhibitor: rofecoxib","volume":"12","author":"Wu","year":"2002","journal-title":"Zhongguo Yaowu Huaxue Zazhi"},{"key":"2024103109400857600_cit307","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1185\/030079902125000796","article-title":"Patient and physician satisfaction with rofecoxib in osteoarthritis: results of a postmarketing surveillance study in primary care in Germany","volume":"18","author":"Zacher","year":"2002","journal-title":"Curr. Med. Res. Opin."},{"key":"2024103109400857600_cit308","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0149-2918(01)80121-1","article-title":"A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization\/Uppsala Monitoring Centre safety database","volume":"23","author":"Zhao","year":"2001","journal-title":"Clin. Ther."},{"key":"2024103109400857600_cit309","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/jnci\/91.14.1186","article-title":"Early trials probe COX-2 inhibitors' cancer-fighting potential","volume":"91","author":"Ziegler","year":"1999","journal-title":"J. Natl Cancer Inst."}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1211%2F0022357021387","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/55\/7\/859\/60260064\/0022357021387.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/55\/7\/859\/60260064\/0022357021387.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T10:15:31Z","timestamp":1730369731000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/55\/7\/859\/6150365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7,1]]},"references-count":309,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2003,7,1]]},"published-print":{"date-parts":[[2003,7,1]]}},"URL":"https:\/\/doi.org\/10.1211\/0022357021387","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2003,7]]},"published":{"date-parts":[[2003,7,1]]}}}